A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
Genetic and molecular changes in ovarian cancer
Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer
The molecular pathology of ovarian serous borderline tumors
Previous
Previous
2017
Next
Next